PUBLIC CONTRACT · 2024
Infliximab 100 mg (biossimilar) remsima pó conc sol inj fr IV
- Contract value
- €127,500.00
- Signed on
- 17 April 2024
- Procedure
- Direct award, general (Ajuste Direto Regime Geral)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 11126022PUBLISHED SUBJECT
INFLIXIMAB 100 MG (BIOSSIMILAR) REMSIMA PÓ CONC SOL INJ FR IV
Parties involved
- Place of performance
- Portugal, Setúbal, Almada
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- PHARMAKERN PORTUGAL - PRODUTOS FARMACÊUTICOS, SOCIEDADE UNIPESSOAL LDA. · Tax ID 507002571
Values and timeline
- Contract price
- €127,500.00
- Procedure base price
- €129,000.00
- Total effective price
- Not reported on Portal BASE
- Publication date
- 3 January 2025
- Award date
- 17 April 2024
- Signing date
- 17 April 2024
- Performance period
- 243 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Direct award, general (Ajuste Direto Regime Geral)
- Award criterion
- Monofator
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- Artigo 24.º, n.º 1, alínea e), subalínea ii) do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos ( DL 111-B/2017 )
- Framework agreement
- Not stated
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 7390586
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.